These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 17032555)

  • 1. Gastrointestinal stromal tumors: imatinib and beyond.
    Schnadig ID; Blanke CD
    Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in therapy for gastrointestinal stromal tumors.
    Maki RG
    Curr Oncol Rep; 2007 May; 9(3):165-9. PubMed ID: 17430686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal stromal tumors: current management.
    Pisters PW; Patel SR
    J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?
    Nilsson B; Nilsson O; Ahlman H
    Expert Opin Investig Drugs; 2009 Apr; 18(4):457-68. PubMed ID: 19335275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
    Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
    Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
    Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches to imatinib- and sunitinib-resistant GIST.
    Reichardt P
    Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
    Pantaleo MA; Di Battista M; Catena F; Astorino M; Saponara M; Di Scioscio V; Santini D; Piazzi G; Castellucci P; Brandi G; Biasco G
    J Cancer Res Clin Oncol; 2008 May; 134(5):625-30. PubMed ID: 18202855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-kit, GIST, and imatinib.
    Siehl J; Thiel E
    Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current management of gastrointestinal stromal tumors--a comprehensive review.
    Lai EC; Lau SH; Lau WY
    Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 19. Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
    Sjölund K; Andersson A; Nilsson E; Nilsson O; Ahlman H; Nilsson B
    World J Surg; 2010 Sep; 34(9):2090-7. PubMed ID: 20512492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
    Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.